Interestingly, Mifepristone, a GR antagonist, resolved psychosis and depression symptoms in Cushing’s patients (van der Lely et al, 1991; Chu et al, 2001) but was not effective in MDD patients without Cushing’s syndrome (Table 1), aligning with our results. This evidence concerns the gene NR3C1 and depressive symptom measurement.